Ginkgo Bioworks Holdings, Inc. – NYSE:DNA

Add to watchlist

$12.178

+2.51

+26.07%

Market closed

Open in 2 days

+3253.00%

month

+3253.00%

quarter

+445.76%

year

Market Cap	555.82M
Enterprise value	1.61B

P/E	-1.01
EV/Sales	3.34
EV/EBITDA	-0.53
Price/Sales	5.16
Price/Book	1.43
PEG ratio	0.20
EPS	-0.44

Revenue	208.69M
EBITDA	-485.86M
Income	-853.81M
Revenue Q/Q	-52.98%
Revenue Y/Y	-46.48%

Profit margin	-630.58%
Oper. margin	-674.19%
Gross margin	57.04%
EBIT margin	-674.19%
EBITDA margin	-232.81%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA): Profit margin
Jun 2023	80.56M	-173.31M	-215.12%
Sep 2023	55.43M	-302.89M	-546.44%
Dec 2023	34.75M	-211.69M	-609.1%
Mar 2024	37.94M	-165.91M	-437.25%

Ginkgo Bioworks Holdings Financials Estimate

Q Y

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA): Analyst Estimates
Mar 2024	37.94M	-165.91M	-437.25%
Sep 2025	86.13M	-158.21M	-183.69%
Oct 2025	63.83M	-93.20M	-146.02%
Dec 2025	68.33M	-74.36M	-108.83%

Analysts Price target
Financials & Ratios estimates

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA): Earnings per share (EPS)
2024-02-29	-0.09	-0.09

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA): Debt to assets
Jun 2023	2291999000	788.41M	34.4%
Sep 2023	2026392000	773.70M	38.18%
Dec 2023	1665342000	568.19M	34.12%
Mar 2024	1581761000	594.49M	37.58%

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA): Cash Flow
Jun 2023	-73.53M	-11.22M	-1.38M
Sep 2023	-73.55M	-3.38M	-315K
Dec 2023	-48.55M	-46.67M	-632K
Mar 2024	-89.25M	-12.11M	-845K

Ginkgo Bioworks Holdings alternative data

Ginkgo Bioworks Holdings
Employees

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA): Employee count
Aug 2023	1,292
Sep 2023	1,292
Oct 2023	1,292
Nov 2023	1,292
Dec 2023	1,292
Jan 2024	1,292
Feb 2024	1,292
Mar 2024	1,218
Apr 2024	1,218
May 2024	1,218
Jun 2024	1,218
Jul 2024	1,218

Ginkgo Bioworks Holdings
Hedge Funds Holdings Q1 2023

36.24% -24.47%

of DNA is owned by hedge funds

211 -101

hedge funds hold DNA stock

608.80M -381.27M

shares is hold by hedge funds

DNA hedge funds holdings changes

Ginkgo Bioworks Holdings
Insider Trading

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	245794
Feb 2024	0	39569
Mar 2024	0	38826
Apr 2024	0	51169
May 2024	922619	2171790
Jun 2024	0	62306
Jul 2024	0	62682
Aug 2024	0	81053
Sep 2024	0	1464
Oct 2024	0	1523
Nov 2024	0	1655
Dec 2024	0	1071

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	4 Dec 2024	COEN STEVEN P. officer: See remarks officer: See remarks	Class A Common Stock	330	$9.64	$3,183
Sale	4 Dec 2024	DMYTRUK MARK E. officer: See remarks officer: See remarks	Class A Common Stock	741	$9.64	$7,146
Option	3 Dec 2024	COEN STEVEN P. officer: See remarks officer: See remarks	Restricted Stock Units	587	N/A	N/A
Option	3 Dec 2024	COEN STEVEN P. officer: See remarks officer: See remarks	Class A Common Stock	156	N/A	N/A
Option	3 Dec 2024	COEN STEVEN P. officer: See remarks officer: See remarks	Class A Common Stock	587	N/A	N/A
Option	3 Dec 2024	COEN STEVEN P. officer: See remarks officer: See remarks	Restricted Stock Units	156	N/A	N/A
Option	3 Dec 2024	DMYTRUK MARK E. officer: See remarks officer: See remarks	Class A Common Stock	8	N/A	N/A
Option	3 Dec 2024	DMYTRUK MARK E. officer: See remarks officer: See remarks	Class A Common Stock	572	N/A	N/A
Option	3 Dec 2024	DMYTRUK MARK E. officer: See remarks officer: See remarks	Class A Common Stock	453	N/A	N/A
Option	3 Dec 2024	DMYTRUK MARK E. officer: See remarks officer: See remarks	Class A Common Stock	484	N/A	N/A

DNA insider trading transactions

Ginkgo Bioworks Holdings
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 9 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 29 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 10 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 10 Aug 2023	Q2 2023 Earnings Call Transcript

DNA earnings call transcripts

Ginkgo Bioworks Holdings
Executives

Insider	Age	Since	Compensation
Dr. Jason Kelly (1981) Co-Founder, Chief Executive Officer & Director	44		$679,090
Mr. Mark E. Dmytruk (1971) Chief Financial Officer	54		$444,200

Ginkgo Bioworks Holdings
Latest News

Wednesday, 18 December 2024
09:00	Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA	accesswire.com
Tuesday, 17 December 2024
16:05	Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines	accesswire.com
13:01	All You Need to Know About Ginkgo Bioworks (DNA) Rating Upgrade to Buy	zacks.com
08:11	Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program	prnewswire.com
Monday, 16 December 2024
10:00	Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out	accesswire.com
Tuesday, 10 December 2024
15:03	Ferrari has Formula One in its DNA, CEO says after Cadillac supply deal	reuters.com
Monday, 18 November 2024
10:36	Ginkgo Bioworks: Unproven Transition But 2025 Is Looking Better	seekingalpha.com
Wednesday, 13 November 2024
08:36	Ginkgo Bioworks: Not Enough Progress	seekingalpha.com
Tuesday, 12 November 2024
22:02	Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call Transcript	seekingalpha.com
20:00	Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
17:01	What's happening with 23andMe? Mass layoffs and restructuring are the latest blow for the embattled DNA testing company	fastcompany.com
17:01	Ginkgo Bioworks Reports Third Quarter 2024 Financial Results	prnewswire.com
08:01	Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics Manufacturing	prnewswire.com
Monday, 11 November 2024
08:30	Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care	businesswire.com
Tuesday, 5 November 2024
07:00	Ginkgo Bioworks Announces Date of Third Quarter 2024 Results Presentation	prnewswire.com
Monday, 4 November 2024
19:20	Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market	zacks.com
Wednesday, 30 October 2024
07:15	Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement	accesswire.com
Tuesday, 29 October 2024
09:05	PacBio Announces SPRQ Chemistry for Revio Sequencing Systems, a Major Advance Reducing the Cost of a HiFi Human Genome to less than $500	globenewswire.com
Monday, 28 October 2024
05:14	DNA & RNA Banking Services Market Report 2024-2030, Featuring EasyDNA, DNA Genotek, 23andMe, GoodCell, ProteoGenex, Infinity Biologix, deCODE genetics, LGC Biosearch Technologies & PreventionGenetics	globenewswire.com
Wednesday, 23 October 2024
07:05	Modifi Biosciences Acquired by Merck	globenewswire.com
Tuesday, 15 October 2024
10:30	Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16	accesswire.com
08:04	Pet DNA Testing Market Report 2024: Industry Analysis and Forecast (2018-2030) with Share & Strategy Insights of Leading Players - Zoetis (Basepaws), Mars Petcare (Wisdom Panel), Orivet Genetic Pet Care & More	globenewswire.com
Thursday, 3 October 2024
11:01	KBRA Assigns Preliminary Ratings to Freddie Mac's STACR 2024-DNA3	businesswire.com
07:03	Virica Biotech and Ginkgo Bioworks Announce Partnership to Accelerate AAV Gene Therapy Manufacturing	businesswire.com
Thursday, 26 September 2024
19:21	Ginkgo Bioworks Holdings, Inc. (DNA) Stock Slides as Market Rises: Facts to Know Before You Trade	zacks.com
Wednesday, 25 September 2024
16:05	Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis	globenewswire.com
16:05	PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples	globenewswire.com
Tuesday, 24 September 2024
07:01	NOVUS Leverages Ginkgo Bioworks to Develop Innovative Feed Additives for Animal Agriculture	prnewswire.com
Wednesday, 18 September 2024
09:00	Pomerantz LLP Announces that this is a Reminder of a Proposed Class Action Settlement on Behalf of Purchasers of Ginkgo Bioworks Holdings, Inc. Common Stock - DNA	globenewswire.com
09:00	Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement	accesswire.com

Ideas & Opinions

Seeking Alpha 11 Apr 2025

Buy Certara After The FDA Announcement
Seeking Alpha 21 Nov 2023

Ginkgo Bioworks: A Long Way To Go
Seeking Alpha 25 Oct 2023

Porter's 5 Forces Suggest That Ginkgo Is A Buy
Seeking Alpha 10 Oct 2023

Ginkgo Bioworks: Products Progressing Towards Market
Seeking Alpha 30 Aug 2023

Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)
Seeking Alpha 8 Feb 2023

Ginkgo: Standardizing Offerings For Growth
Seeking Alpha 16 Nov 2022

Ginkgo Bioworks: Strange Equity Offering
Seeking Alpha 7 Nov 2022

From Spending Cash To Fermenting Money: Amyris Is Fit To Profit From High ROI Plants And Innovative Marketing
Seeking Alpha 24 Oct 2022

Cronos Group: $1 Billion Of Net Cash, Pure-Play Cannabis Operator
Seeking Alpha 5 Oct 2022

Ginkgo Bioworks: Business Model Uncertainty

Frequently Asked Questions (FAQ)

What's the price of Ginkgo Bioworks Holdings stock today?

One share of Ginkgo Bioworks Holdings stock can currently be purchased for approximately $12.18.
When is Ginkgo Bioworks Holdings's next earnings date?

Unfortunately, Ginkgo Bioworks Holdings's (DNA) next earnings date is currently unknown.
Does Ginkgo Bioworks Holdings pay dividends?

No, Ginkgo Bioworks Holdings does not pay dividends.
How much money does Ginkgo Bioworks Holdings make?

Ginkgo Bioworks Holdings has a market capitalization of 555.82M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 47.36% to 251.46M US dollars. Ginkgo Bioworks Holdings made a loss 892.87M US dollars in net income (profit) last year or -$0.09 on an earnings per share basis.
What is Ginkgo Bioworks Holdings's stock symbol?

Ginkgo Bioworks Holdings, Inc. is traded on the NYSE under the ticker symbol "DNA".
What is Ginkgo Bioworks Holdings's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Ginkgo Bioworks Holdings?

Shares of Ginkgo Bioworks Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Ginkgo Bioworks Holdings's key executives?
Ginkgo Bioworks Holdings's management team includes the following people:
- Dr. Jason Kelly Co-Founder, Chief Executive Officer & Director(age: 44, pay: $679,090)
- Mr. Mark E. Dmytruk Chief Financial Officer(age: 54, pay: $444,200)
Is Ginkgo Bioworks Holdings founder-led company?

Yes, Ginkgo Bioworks Holdings is a company led by its founder Dr. Jason Kelly.
How many employees does Ginkgo Bioworks Holdings have?

As Jul 2024, Ginkgo Bioworks Holdings employs 1,218 workers.
When Ginkgo Bioworks Holdings went public?

Ginkgo Bioworks Holdings, Inc. is publicly traded company for more then 4 years since IPO on 19 Apr 2021.
What is Ginkgo Bioworks Holdings's official website?

The official website for Ginkgo Bioworks Holdings is ginkgobioworks.com.
Where are Ginkgo Bioworks Holdings's headquarters?

Ginkgo Bioworks Holdings is headquartered at 27 Drydock Avenue, Boston, MA.
How can i contact Ginkgo Bioworks Holdings?

Ginkgo Bioworks Holdings's mailing address is 27 Drydock Avenue, Boston, MA and company can be reached via phone at 877 422 5362.

Ginkgo Bioworks Holdings, Inc.

ginkgobioworks.com

Exchange:

NYSE

Full time employees:

1,218

Industry:

Biotechnology

Sector:

Healthcare

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

877 422 5362

27 Drydock Avenue
Boston, MA 02210

CIK: 0001830214
ISIN: US37611X1000
CUSIP: 37611X100